5/9/2025

Janusmed sex and gender

Janusmed sex and gender – Ruxolitinib – systemic use

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
C! C!
C! C!

Ruxolitinib – systemic use

Ruxolitinib – systemic use

Class : C!

Show all info

Print

Contact us

  1. What is the Life Expectancy for Someone with Myelofibrosis?. Health Tree Foundation [www]. [cited 2024-11-14].

  2. Penna D, Lasho TL, Finke CM, Vallapureddy RR, Hanson CA, Ketterling RP et al. 20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long-lived patients. Am J Hematol. 2019;94(3):286-290.

  3. Verstovsek S, Yeleswaram S, Hou K, Chen X, Erickson-Viitanen S. Sustained-release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis. Hematol Oncol. 2018;36(4):701-708.

  4. Gong X, Chen X, Kuligowski ME, Liu X, Liu X, Cimino E et al. Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies. Am J Clin Dermatol. 2021;22(4):555-566.

  5. Barraco D, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A et al. Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. Blood Cancer J. 2018;8(10):89.

  6. Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015;100(9):1139-45.

  7. Lee BH, Moon H, Chae JE, Kang KW, Kim BS, Lee J et al. Clinical Efficacy of Ruxolitinib in Patients with Myelofibrosis: A Nationwide Population-Based Study in Korea. J Clin Med. 2021;10(20):.

  8. Jakavi (ruxolitinib). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2024-03-21, cited 2024-11-14]

  9. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2023 [cited 2024-03-06.]

  1. What is the Life Expectancy for Someone with Myelofibrosis?. Health Tree Foundation [www]. [cited 2024-11-14].
  2. Penna D, Lasho TL, Finke CM, Vallapureddy RR, Hanson CA, Ketterling RP et al. 20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long-lived patients. Am J Hematol. 2019;94(3):286-290.
  3. Verstovsek S, Yeleswaram S, Hou K, Chen X, Erickson-Viitanen S. Sustained-release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis. Hematol Oncol. 2018;36(4):701-708.
  4. Gong X, Chen X, Kuligowski ME, Liu X, Liu X, Cimino E et al. Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies. Am J Clin Dermatol. 2021;22(4):555-566.
  5. Barraco D, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A et al. Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. Blood Cancer J. 2018;8(10):89.
  6. Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015;100(9):1139-45.
  7. Lee BH, Moon H, Chae JE, Kang KW, Kim BS, Lee J et al. Clinical Efficacy of Ruxolitinib in Patients with Myelofibrosis: A Nationwide Population-Based Study in Korea. J Clin Med. 2021;10(20):.
  8. Jakavi (ruxolitinib). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2024-03-21, cited 2024-11-14]
  9. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2023 [cited 2024-03-06.]